Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of $305.46 billion. The enterprise value is $316.57 billion.
| Market Cap | 305.46B |
| Enterprise Value | 316.57B |
Important Dates
The next confirmed earnings date is Wednesday, May 7, 2025, before market open.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | Mar 31, 2025 |
Share Statistics
Novo Nordisk has 4.44 billion shares outstanding. The number of shares has decreased by -0.71% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.44B |
| Shares Change (YoY) | -0.71% |
| Shares Change (QoQ) | -0.11% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.18B |
Valuation Ratios
The trailing PE ratio is 21.79 and the forward PE ratio is 17.21.
| PE Ratio | 21.79 |
| Forward PE | 17.21 |
| PS Ratio | 7.58 |
| Forward PS | 0.89 |
| PB Ratio | 15.34 |
| P/TBV Ratio | 67.92 |
| P/FCF Ratio | 28.52 |
| P/OCF Ratio | 18.19 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.55, with an EV/FCF ratio of 29.56.
| EV / Earnings | 22.58 |
| EV / Sales | 7.85 |
| EV / EBITDA | 15.55 |
| EV / EBIT | 16.30 |
| EV / FCF | 29.56 |
Financial Position
The company has a current ratio of 0.74, with a Debt / Equity ratio of 0.72.
| Current Ratio | 0.74 |
| Quick Ratio | 0.52 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 0.69 |
| Debt / FCF | 1.33 |
| Interest Coverage | 85.29 |
Financial Efficiency
Return on equity (ROE) is 80.78% and return on invested capital (ROIC) is 46.03%.
| Return on Equity (ROE) | 80.78% |
| Return on Assets (ROA) | 22.41% |
| Return on Invested Capital (ROIC) | 46.03% |
| Return on Capital Employed (ROCE) | 56.34% |
| Revenue Per Employee | $521,201 |
| Profits Per Employee | $181,248 |
| Employee Count | 77,349 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 1.20 |
Taxes
In the past 12 months, Novo Nordisk has paid $3.64 billion in taxes.
| Income Tax | 3.64B |
| Effective Tax Rate | 20.60% |
Stock Price Statistics
The stock price has decreased by -45.88% in the last 52 weeks. The beta is 0.17, so Novo Nordisk's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | -45.88% |
| 50-Day Moving Average | 82.44 |
| 200-Day Moving Average | 110.98 |
| Relative Strength Index (RSI) | 28.89 |
| Average Volume (20 Days) | 7,090,034 |
Short Selling Information
The latest short interest is 12.64 million, so 0.40% of the outstanding shares have been sold short.
| Short Interest | 12.64M |
| Short Previous Month | 13.53M |
| Short % of Shares Out | 0.40% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.57 |
Income Statement
In the last 12 months, Novo Nordisk had revenue of $40.31 billion and earned $14.02 billion in profits. Earnings per share was $3.14.
| Revenue | 40.31B |
| Gross Profit | 34.27B |
| Operating Income | 19.42B |
| Pretax Income | n/a |
| Net Income | 14.02B |
| EBITDA | 20.36B |
| EBIT | 19.42B |
| Earnings Per Share (EPS) | $3.14 |
Balance Sheet
The company has $3.65 billion in cash and $14.27 billion in debt, giving a net cash position of -$10.62 billion or -$2.39 per share.
| Cash & Cash Equivalents | 3.65B |
| Total Debt | 14.27B |
| Net Cash | -10.62B |
| Net Cash Per Share | -$2.39 |
| Equity (Book Value) | 19.92B |
| Book Value Per Share | 4.49 |
| Working Capital | -7.86B |
Cash Flow
In the last 12 months, operating cash flow was $16.79 billion and capital expenditures -$6.55 billion, giving a free cash flow of $10.71 billion.
| Operating Cash Flow | 16.79B |
| Capital Expenditures | -6.55B |
| Free Cash Flow | 10.71B |
| FCF Per Share | $2.41 |
Margins
Gross margin is 85.00%, with operating and profit margins of 48.17% and 34.78%.
| Gross Margin | 85.00% |
| Operating Margin | 48.17% |
| Pretax Margin | 43.80% |
| Profit Margin | 34.78% |
| EBITDA Margin | 50.51% |
| EBIT Margin | 48.17% |
| FCF Margin | 26.57% |
Dividends & Yields
This stock pays an annual dividend of $1.30, which amounts to a dividend yield of 1.88%.
| Dividend Per Share | $1.30 |
| Dividend Yield | 1.88% |
| Dividend Growth (YoY) | -5.23% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 41.38% |
| Buyback Yield | 0.71% |
| Shareholder Yield | 2.58% |
| Earnings Yield | 4.59% |
| FCF Yield | 3.51% |
Analyst Forecast
The average price target for Novo Nordisk is $141.67, which is 104.43% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $141.67 |
| Price Target Difference | 104.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 12.18% |
| EPS Growth Forecast (5Y) | 14.16% |
Stock Splits
The last stock split was on September 20, 2023. It was a forward split with a ratio of 2:1.
| Last Split Date | Sep 20, 2023 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novo Nordisk has an Altman Z-Score of 8.94 and a Piotroski F-Score of 5.
| Altman Z-Score | 8.94 |
| Piotroski F-Score | 5 |